贝伐单抗治疗晚期肿瘤不良反应的临床观察

摘要

目的：观察贝伐单抗在恶性肿瘤治疗过程中的不良反应。方法：52例晚期恶性肿瘤患者，给予贝伐单抗7．5mg/（kg·3w），3周为1观察周期，5mg/（kg·2w），4周为1观察周期，单药或联合化疗，观察患者的主要不良反应。结果：52例患者共接受134周期治疗。主要不良反应为高血压（19．2％）、出血（13．5％）和蛋白尿（9．6％），其中3例发生血栓栓塞、1例发生严重心肌缺血不能耐受继续治疗。结论：贝伐单抗的主要不良反应为高血压、出血和蛋白尿，多为I-II级。不良反应发生率低，耐受性好。%Objective:To investigate the toxicities of bevacizumab.Methods:Total of 52 patients with advanced cancer were treated with bevacizumab 7.5mg/m2 or plus chemotherapy at intervals of 3 weeks.Results:All 52 pa-tients were treated with bevacizumab and totally 134 treatment cycles were completed.Hypertension(19.2%),pro-teinuria (13.5%)and bleeding (9.6%)were the main toxicities,3 patients with thrombotic infarct and 1 patient shuffered from myocardial ischemia could not be treated with bevacizumab again.Conclusion:Hypertension,proteinu-ria and bleeding were the main toxicities of bevacizumab,most were grade I and grade II,with low tox-side reaction, bevacizumab is well tolerated by the patients.